Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist in Ambulatory Hematology
Adjunct Clinical Instructor
Rotation(s) Offered: Ambulatory Oncology


I am a clinical specialist caring for patients with malignant and non-malignant hematologic disorders in the ambulatory setting. I precept APPE, PGY1 and PGY2 learners. 

Pharmacy School Attended: University at Buffalo (2016)

Additional Training: 

  • PGY1 Pharmacy: University of Michigan (2017) 
  • PGY2 Oncology: University of Michigan (2018)

Areas of Interest

 Improving clinical outcomes in hematology patients, oncology stewardship , and expanding the role of the oncology pharmacist

Honors & Awards

Preceptor of the year- Michigan Medicine Oncology Pharmacy Residency (2021)
HOPA Basic Science and Clinical Research Literature Award (2021)
Michigan Medicine Quality Month Exemplar Finalist (2020)
MSHP President’s Award, Awarded to Michigan Medicine Rogel Cancer Center Ambulatory Oncology Pharmacists (2019)

Published Articles or Reviews

Schaefer JK, Elshoury A, Streiff MB, Nachar VR, Lim MY. How to Choose An Appropriate Anticoagulant for Cancer Associated Thrombosis. JNCCN. 2021.

Baek GT, Marini BL, Perissinotti AJ, Brown A, Nachar VR. Complications with obinutuzumab or rituximab with bendamustine versus obinutuzumab or rituximab with CHOP/CVP in patients with indolent non-Hodgkins Lymphoma. Leukemia & Lymphoma. 2021. doi: 10.1080/10428194.2021.1953014.

Homan M, Reid J, Nachar VR, Benitez LL, Brown AM, Kraft S, Hough S, Christen C, Frame D, McDevitt RL. Implementation and Outcomes of a Pharmacist-led Collaborative Drug Therapy Management Program for Oncology Symptom Management. Support Care Cancer. 2021. doi: 10.1007/s00520-021-06239-0

Hough S, McDevitt R, Nachar VR, Kraft S, Brown A, Christen C, Frame D, Smerage J. Chemotherapy remote care monitoring program: Integration of SMS text patient-reported outcomes in the electronic health record and pharmacist intervention for chemotherapy-induced nausea and vomiting. JCO Oncol Pract. 2021;OP2000639. doi: 10.1200/OP.20.00639.

Bazzel BG, Benitez LL, Marini BL, Perissinotti AJ, Phillips TJ, Nachar VR. Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2020;S2152-2650(20)31039-9.

Nachar VR, Schepers A. Clinical Controversies in Cancer-Associated Venous Thromboembolism. J Oncol Pharm Pract. 2021;1078155220984371. doi: 10.1177/1078155220984371.

Tam A, Schepers A, Qin A, Nachar VR. Effect of extended interval versus standard dosing of zoledronic acid on skeletal events in non-small cell and small cell lung cancer patients with bone metastases. Ann Pharmacother. 2020. doi: 10.1177/1060028020967629.

Reid JH, Marini BL, Nachar VR, Brown AM, Devata S, Perissinotti AJ. Contemporary treatment options for a classical disease: advanced Hodgkin lymphoma. Critical Reviews in Oncology/Hematology. 2020;148:102897.

Weis T, Marini BL, Nachar VR, Brown A, Brown J, Phillips T, Perissinotti AJ. Impact of a vincristine dose cap on incidence of neuropathies with DA-R-EPOCH for treatment of aggressive lymphomas. Leukemia & Lymphoma. 2019; DOI: 10.1080/10428194.2019.1703969

Robinson A, Nachar VR. Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma. Journal of Oncology Pharmacy Practice. 2019; DOI: 10.1177/1078155219890023.

Hoylmann E, Brown A, Perissinotti AJ, Marini BM, Pianko M, Ye J, Campagnaro E, Nachar VR. Optimal sequence of daratumumab and elotuzumab in relapsed refractory multiple myeloma. Leukemia & Lymphoma. 2019; 18:1-8.

Weis TM, Perissinotti AJ, Nachar VR, Brown AM, Phillips TJ, Marini BL. Dosing Vincristine in Dose-Adjusted EPOCH-R: To Cap or Not to Cap? Journal of Clinical Oncology. 2019; 37(31):2952.

Nachar VR, Farris K, Beekman K, Griggs J, Hough S, Mackler E. Clinician Report of Oral Oncolytic Symptoms and Adherence Obtained Via a Patient Reported Outcome Measure (PROM). JCO Clinical Cancer Informatics. 2019; 3:1-6.

Reid J, Marini BL, Nachar VR, Devata S, Perissinotti AJ. Upfront eBEACOPP PET-adapted strategy: is the damage already done? Lancet Oncology. 2019; 20(4):e188.

Vulaj V, Perissinotti AJ, Uebel JR, Nachar VR, Scappaticci GB, Crouch A, Bixby DL, Maillard I, Talpaz M, Marini BL. The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. Leukemia Research. 2018; 70:91-96.

Scappaticci GB, Marini BL, Nachar VR, Uebel JR, Vulaj V, Crouch A, Bixby DL, Talpaz M, Perissinotti AJ. Outcomes for Previously Untreated Elderly Patients with AML: A Propensity Score Matched Comparison of Clofarabine vs FLAG. Annal of Hematol. 2017. 97(4):573-584

Nachar VR, Perissinotti AJ, Scappaticci GB, Bixby DL, Marini BL. Predictors for Requiring Re-Induction Chemotherapy in Acute Myeloid Leukemia Patients with Residual Disease on Day 14 Bone Marrow Assessment. Leukemia Research. 2017;63:56-61.